FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Longevity In Vitro Research Only

Sermorelin: Reversing GH Decline, Improving Sleep & Anti-Aging Research

29 Amino Acids — FDA-Studied GHRH Fragment

Sermorelin is a 29-amino-acid analogue of GHRH (the biologically active fragment GHRH[1-29]) and the only GHRH analogue formerly FDA-approved. Unlike synthetic HGH, sermorelin operates through the body's own feedback systems — preserving natural hypothalamic-pituitary feedback so GH release remains subject to somatostatin inhibition. Research by Donahue et al. (2019) demonstrated sermorelin reduced amyloid-beta accumulation and improved cerebral blood flow in an Alzheimer's mouse model.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

⚗️

Pituitary GHRH Receptor Activation

Directly stimulates pituitary GHRH receptors to produce pulsatile GH secretion while preserving hypothalamic-pituitary feedback — a self-regulating mechanism absent in exogenous HGH.

🧬

Somatopause Reversal

Walker et al. showed sermorelin therapy restored GH pulsatility to youthful patterns in men with adult GH deficiency, improving lean mass and reducing fat mass.

😴

Slow-Wave Sleep Architecture

Van Cauter et al. demonstrated sermorelin deepens slow-wave sleep in elderly subjects — creating a positive loop: better sleep → more GH → enhanced cellular repair.

🧠

Amyloid-Beta Reduction

Preclinical data show sermorelin reduced amyloid-beta plaque accumulation and improved cognitive scores in Alzheimer's mouse models, opening GH-axis restoration as a dementia prevention strategy.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

💊
FDA
Former Approval Status
Only GHRH analogue approved
🧠
↓Aβ
Amyloid-Beta Reduction
Preclinical Alzheimer's model
😴
+SWS
Slow-Wave Sleep Depth
Van Cauter et al. (2000)
⚖️
Self-Reg
Feedback Preserved
Somatostatin inhibition intact

Sermorelin Outcomes vs. Baseline — Body Composition & Quality of Life

Lean Body Mass
44
Fat Mass Reduction
38
GH Pulsatility
62
Sleep Quality
51
QoL Score
47

Data from Walker et al. (2004) Clin Interv Aging. GH-deficient adult male subjects. Preclinical / observational data.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

95%

Tolerability

Low Severity
14%

Injection-Site Rxn

Low Severity
8%

Headache (Transient)

Low Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.

RESEARCH CITATIONS

Primary literature — links open PubMed or original journal source

Syntra Compound Library

View SERMORELIN specifications, batch data, and Certificate of Analysis in the Syntra research compound catalogue.

View SERMORELIN in the Syntra Compound Library →

For in vitro laboratory research use only. Not for human consumption.

← Back to Peptide Research Library
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →